• Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference

    Source: Nasdaq GlobeNewswire / 03 Aug 2021 07:30:00   America/Chicago

    CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Steven Bellon, Ph.D., Senior Vice President of Drug Discovery, is scheduled to participate in a panel at the 2021 Wedbush PacGrow Healthcare Virtual Conference, which is being held from August 10-11.

    Panel Details:
    Title: “Bullseye – Targeted Oncology Part 2”
    Panel date and time: Wednesday, August 11, 10:20 a.m. ET

    Members of the Foghorn management team will also host investor meetings during the conference.

    A live webcast of the panel can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com.

    About Foghorn Therapeutics

    Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

    Media Contact:

    Fanny Cavalié, Foghorn Therapeutics
    fcavalie@foghorntx.com

    Gregory Kelley, Ogilvy
    gregory.kelley@ogilvy.com

    Investor Relations Contact:

    Allan Reine, Foghorn Therapeutics
    areine@foghorntx.com

    Hans Vitzthun, LifeSci Advisors
    617-430-7578
    hans@lifesciadvisors.com


    Primary Logo

Share on,